Prevalence of Monogenic Aetiologies of Kidney Stone Disease in Selected and Unselected Kidney Stone Cohorts

This study demonstrates that genetic testing for monogenic kidney stone disease yields a significantly higher diagnostic rate in specialist clinical settings compared to unselected populations, while standard serum biochemistry fails to reliably identify at-risk individuals.

The Gist

Imagine your kidneys are like a sophisticated water filtration plant. Usually, when stones form in these plants, it's because of "bad weather" or "operator error"—things like drinking too little water, eating too much salt, or having a diet high in oxalates. These are common problems, and doctors usually treat them with lifestyle changes or standard blood tests.

But sometimes, the problem isn't the weather; it's a flaw in the blueprints of the factory itself. These are "monogenic" kidney stones, caused by a single typo in your genetic code.

This paper is like a massive investigation comparing two groups of people to figure out: Who has these blueprint errors, how often do they happen, and can we spot them just by looking at the factory's daily reports (blood tests)?

Here is the breakdown of their findings using simple analogies:

1. The Two Detective Teams

The researchers looked at two different groups of people to solve the mystery:

• Team A (The General Population): They looked at the UK Biobank, which is like a giant, random crowd of 500,000 volunteers. Some of these people had kidney stones, but most didn't. This represents the "unselected" crowd—people walking into a regular clinic.
• Team B (The Specialists): They looked at a Specialist Stone Clinic in Newcastle. These are people who have been sent to experts because their stones are weird, they come back constantly, or they started having them when they were very young. This is the "selected" crowd.

2. The "Blueprint" Mystery (Genetics)

For a long time, doctors were confused about how these genetic errors were passed down. Was it like a dominant trait (one bad copy ruins the whole factory)? Or recessive (you need two bad copies to cause a problem)?

The researchers acted like genetic detectives, testing specific genes (like SLC34A3, SLC7A9, and CYP24A1) to see how they behaved.

• The Findings: They figured out the rules.
  • Some genes (like the ones causing Cystinuria) act like a dominant trait. If you have just one bad copy of the blueprint, you are at high risk. It's like having one cracked pipe that leaks immediately.
  • Other genes (like CYP24A1) act like a recessive trait. You need two bad copies (one from mom, one from dad) to get sick. If you only have one, the factory usually keeps running fine.

3. The "Need to Test" Game (The Big Surprise)

The most important part of the study is answering: "How many people do we need to test to find one person with a genetic error?" They call this the Number Needed to Test (NNTT).

• In the General Crowd (Team A): It was like looking for a needle in a haystack. They had to test about 90 people with kidney stones to find just one person with a genetic cause.
  • Analogy: If you walked into a regular ER with a kidney stone, the odds are very low that your problem is a genetic blueprint error. It's probably just "bad weather."
• In the Specialist Clinic (Team B): It was like looking for a needle in a small pile of hay. They only had to test 7 people to find one with a genetic cause.
  • Analogy: If you are a young person with stones that keep coming back, or you have a family history, the odds skyrocket. Here, the "needle" is much easier to find.

4. The "Blood Test" Trap

Doctors often look at blood tests (checking calcium and phosphate levels) to guess if a patient has a genetic disease. The researchers asked: "Do these blood tests work as a warning light?"

• The Result: The warning lights were broken.
  • Many people with confirmed genetic errors had completely normal blood tests.
  • Analogy: Imagine a car with a broken engine (genetic disease), but the dashboard says "All Systems Go" (normal blood work). If you only look at the dashboard, you miss the problem entirely.
  • Specifically, for the most common genetic stone type (Cystinuria), the blood tests were useless. You can only find it by looking at the urine or the stone itself.

5. The Takeaway: When to Call the Genetic Detective

The study concludes with a clear rule of thumb for doctors and patients:

1. Don't test everyone: If you are an older adult with a single stone and normal blood work, genetic testing is likely a waste of time and money. You are part of the "90 to find 1" group.
2. Do test the "High Risk" group: If you are young, have stones that keep coming back, or have a family history, you belong to the "7 to find 1" group. Genetic testing is highly valuable here.
3. Why it matters: Finding the genetic "blueprint error" changes the treatment.
   • Some genetic stones need special diets (like avoiding certain proteins).
   • Some need specific medications (like phosphate supplements).
   • Most importantly, it allows you to warn your family members, who might also be carrying the "broken blueprint" without knowing it.

In summary: Kidney stones are usually a lifestyle issue, but for a specific group of high-risk patients, they are a genetic puzzle. Standard blood tests often fail to spot this puzzle, so doctors need to use their clinical judgment (age, history, recurrence) to decide who needs a genetic test. It's about finding the right key for the right lock.

Technical Summary

1. Problem Statement

Kidney Stone Disease (KSD) is a prevalent condition with significant morbidity and recurrence rates. While KSD is often multifactorial, distinct monogenic (Mendelian) forms exist with specific treatment pathways (e.g., cystinuria, primary hyperoxaluria). However, clinical practice faces three major uncertainties:

• Inheritance Patterns: The mode of inheritance for several genes in the standard diagnostic panel (specifically SLC34A1, SLC34A3, CYP24A1, SLC7A9, SLC3A1) remains ambiguous regarding whether monoallelic (heterozygous) or biallelic (homozygous/compound heterozygous) variants are required to cause disease.
• Diagnostic Yield: It is unclear which patient populations benefit most from genetic testing. Diagnostic yields vary widely (3–7% in adults, up to 30% in early-onset cases), but the "Number Needed to Test" (NNTT) in unselected vs. selected cohorts is not well-defined.
• Biochemical Screening: Standard serum biochemistry (calcium, phosphate) is often used to screen for metabolic causes, but its sensitivity for identifying monogenic KSD is unknown.

2. Methodology

The study utilized a dual-cohort approach combining population-scale genomic data with a clinically enriched specialist cohort.

• Cohort 1: UK Biobank (Unselected Population)

  • Sample: ~469,000 participants with Whole Exome Sequencing (WES) data.
  • Definition: KSD cases were identified via ICD codes, OPCS surgical codes, and self-reporting (N=13,681 cases; 455,614 controls).
  • Genetic Analysis: Variants in 35 genes from the NHS Genomic Medicine Service Panel (R256) were analyzed. Variants were classified as Pathogenic (P) or Likely Pathogenic (LP) using ACMG guidelines.
  • Inheritance Modeling: The study tested both monoallelic and biallelic models for genes with uncertain inheritance (CYP24A1, SLC2A9, SLC34A1, SLC34A3, SLC3A1, SLC7A9) by correlating genotype with KSD status and serum biochemistry (phosphate, calcium).

• Cohort 2: Newcastle Specialist Metabolic Stone Clinic (Selected Population)

  • Sample: 243 adult patients (May 2021–Jan 2025) referred based on recurrence, early onset (<30y), or family history.
  • Testing: Patients underwent genetic testing (34-gene panel) and comprehensive phenotyping (serum biochemistry, 24-hour urine, stone analysis).
  • Analysis: Retrospective chart review correlated genetic findings with clinical phenotypes.

• Statistical Analysis:

  • Calculated the Number Needed to Test (NNTT) for both cohorts.
  • Performed multivariable logistic regression to identify predictors of monogenic diagnosis (age, sex, family history, stone burden).
  • Assessed the utility of standard serum phosphate and calcium levels in detecting monogenic cases.

3. Key Contributions

• Clarification of Inheritance Models: The study definitively resolved the inheritance patterns for key genes:
  • Autosomal Dominant (Monoallelic sufficient): SLC34A3 (HHRH), SLC7A9, and SLC3A1 (Cystinuria).
  • Autosomal Recessive (Biallelic required): SLC34A1 and CYP24A1.
  • Note: Monoallelic variants in CYP24A1 and SLC34A1 showed minimal phenotypic impact in the general population, suggesting they do not cause monogenic KSD in isolation.
• Quantification of Diagnostic Yield: Established precise diagnostic rates and NNTT for unselected vs. selected populations.
• Evaluation of Biochemical Screening: Demonstrated that standard serum biochemistry has poor sensitivity for detecting the most common monogenic forms of KSD.

4. Key Results

A. Inheritance Patterns & Genotype-Phenotype Correlation

• SLC34A3: Heterozygous carriers showed lower serum phosphate and increased KSD risk, supporting an autosomal dominant model with incomplete penetrance.
• SLC7A9 & SLC3A1: In the specialist cohort, heterozygous variants were sufficient to cause cystine stones and cystinuria, confirming an autosomal dominant model for these genes in the context of stone disease.
• CYP24A1 & SLC34A1: No significant association was found between heterozygous variants and KSD or biochemical abnormalities in the UK Biobank, supporting a recessive model.

B. Prevalence and Diagnostic Yield

• UK Biobank (Unselected):
  • Monogenic diagnosis rate: ~1.05% of KSD cases vs. 0.81% of controls.
  • NNTT: ~90 for recurrent stone formers and ~93 for single-event formers.
  • Most common findings: SLC7A9 (0.64%) and SLC34A3 (0.37%).
• Specialist Clinic (Selected):
  • Monogenic diagnosis rate: 15% (37/243 patients).
  • NNTT: ~7.
  • Most common diagnoses: Cystinuria (SLC7A9 and SLC3A1, n=24), HHRH (SLC34A3, n=6), and dRTA (SLC4A1, n=3).

C. Predictors of Monogenic Disease

• Age: Younger age at first presentation was the only statistically significant predictor of a monogenic diagnosis (Median 29y vs 30y, p=0.03).
• Non-Predictors: Sex, family history, bilaterality of stones, and number of stone events did not significantly predict a monogenic diagnosis.

D. Utility of Biochemical Screening

• Failure of Serum Phosphate: In the UK Biobank, only 8.5% of SLC34A3 carriers had hypophosphatemia (<0.80 mmol/L). In the specialist clinic, only 1/6 SLC34A3 patients had detectable hypophosphatemia.
• Conclusion: Standard serum biochemistry fails to identify the vast majority of individuals with monogenic KSD. Relying on biochemical abnormalities alone would miss most cases.

5. Significance and Clinical Implications

• Refined Testing Guidelines: The study supports a targeted genetic testing strategy. Genetic testing should be prioritized in specialist settings for patients with clinical suspicion of inherited disorders (e.g., early onset, recurrence), rather than applied broadly to all stone formers (where NNTT >90).
• Panel Interpretation: The findings provide evidence to update clinical genetic panels (e.g., Genomics England Panel R256), clarifying that SLC34A3, SLC7A9, and SLC3A1 should be interpreted under an autosomal dominant model, while CYP24A1 and SLC34A1 require biallelic variants for a monogenic diagnosis.
• Clinical Management: Identifying monogenic causes is critical for:
  • Targeted Therapy: e.g., Oral phosphate for HHRH, specific dietary management for cystinuria.
  • Family Screening: Cascade testing for at-risk relatives.
  • Avoiding Misdiagnosis: Preventing the overcalling of variants in genes like CYP24A1 and SLC34A1 when only heterozygous.
• Limitations: The UK Biobank is a healthy volunteer cohort (age 40–69) and lacks specific phenotypes (e.g., urinary cystine), potentially underestimating prevalence in younger or more severe populations. The specialist cohort is from a single center.

Conclusion: Monogenic KSD is rare in the general population but highly enriched in specialist clinics. Standard biochemical screening is insufficient for detection. Genetic testing is highly efficient in selected, high-risk populations and is essential for precise management and family counseling.